肿瘤(癌症)患者之家
首页
癌症知识
肿瘤中医药治疗
肿瘤药膳
肿瘤治疗技术
前沿资讯
登录/注册
VIP特权

文章目录

放疗后肿瘤细胞对炎症微环境的重塑

Inflammatory microenvironment remodelling by tumour cells after radiotherapy

原文发布日期:2020-03-11

DOI: 10.1038/s41568-020-0246-1

类型: Review Article

开放获取: 否

英文摘要:

摘要翻译: 

原文链接:

文章:

放疗后肿瘤细胞对炎症微环境的重塑

Inflammatory microenvironment remodelling by tumour cells after radiotherapy

原文发布日期:2020-03-11

DOI: 10.1038/s41568-020-0246-1

类型: Review Article

开放获取: 否

 

英文摘要:

The development of immune checkpoint inhibitors (ICIs) is revolutionizing the way we think about cancer treatment. Even so, for most types of cancer, only a minority of patients currently benefit from ICI therapies. Intrinsic and acquired resistance to ICIs has focused research towards new combination therapy approaches that seek to increase response rates, the depth of remission and the durability of benefit. In this Review, we describe how radiotherapy, through its immunomodulating effects, represents a promising combination partner with ICIs. We describe how recent research on DNA damage response (DDR) inhibitors in combination with radiotherapy may be used to augment this approach. Radiotherapy can kill cancer cells while simultaneously triggering the release of pro-inflammatory mediators and increasing tumour-infiltrating immune cells – phenomena often described colloquially as turning immunologically ‘cold’ tumours ‘hot’. Here, we focus on new developments illustrating the key role of tumour cell-autonomous signalling after radiotherapy. Radiotherapy-induced tumour cell micronuclei activate cytosolic nucleic acid sensor pathways, such as cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING), and propagation of the resulting inflammatory signals remodels the immune contexture of the tumour microenvironment. In parallel, radiation can impact immunosurveillance by modulating neoantigen expression. Finally, we highlight how tumour cell-autonomous mechanisms might be exploited by combining DDR inhibitors, ICIs and radiotherapy.

 

摘要翻译: 

免疫检查点抑制剂(ICI)的发展正在彻底改变我们对癌症治疗的认知。然而,就大多数癌症类型而言,目前仅有少数患者能从ICI疗法中获益。对ICI的固有及获得性耐药问题促使研究转向新的联合疗法策略,旨在提高治疗应答率、缓解深度及疗效持久性。本文综述中,我们探讨了放疗如何通过其免疫调节效应成为与ICI联合治疗的有望组合,并阐述了近期关于DNA损伤反应(DDR)抑制剂联合放疗的研究如何增强该策略的疗效。放疗在杀死癌细胞的同时,能触发促炎介质释放并增加肿瘤浸润免疫细胞——这种现象常被通俗地描述为将免疫“冷”肿瘤转化为“热”肿瘤。我们重点分析了放疗后肿瘤细胞自主信号传导的关键作用:放疗诱导的肿瘤细胞微核激活胞质核酸传感通路(如cGAS-STING通路),其产生的炎症信号传导重塑了肿瘤微环境的免疫格局。同时,放疗可通过调节新抗原表达影响免疫监视。最后,我们强调了如何通过联合使用DDR抑制剂、ICI和放疗来利用肿瘤细胞自主机制。

 

原文链接:

Inflammatory microenvironment remodelling by tumour cells after radiotherapy

相关文章

文章:肿瘤抗原优先来源于黑色素瘤和非小细胞肺癌中未突变的基因组序列
文章:年龄相关的烟酰胺腺嘌呤二核苷酸下降驱动CAR-T细胞衰竭
文章:MCSP+转移创始细胞在人类黑色素瘤转移定植早期激活免疫抑制
文章:脂质纳米颗粒递送合成抗原使实体瘤对car介导的细胞毒性敏感
文章:食管癌新辅助治疗中的进化和免疫微环境动力学
文章:CHD1缺失重编程srebp2驱动的胆固醇合成,在spop突变的前列腺肿瘤中促进雄激素响应性生长和去势抵抗
文章:对TIL细胞治疗无反应的转移性非小细胞肺癌患者的T细胞和新抗原保留受损的时间序列分析
文章:策展的癌细胞图谱提供了单细胞分辨率的肿瘤的全面表征
文章:以人群为基础的胶质瘤分子景观分析在青少年和年轻人揭示胶质瘤形成的见解
文章:肿瘤细胞上的PILRα与T细胞表面蛋白CD99相互作用抑制抗肿瘤免疫

……